	0	IPE			PTO/SB/08A (10-07)	
Subs	titute for form 1449A/PTO		86	Complete if Known		
	(_ OCT	197	007	Application Number	10/588,409	
				Filing Date	August 3, 2006	
IN	FORMATION DISC ATEMENT BY AF	JLU (球球)	SORE	First Named Inventor	Tidmarsh, George	
Si	AIEMENI BY AF	PLI	CANI	Art Unit	1624	
	(Use as many sheets as ne	cessar	y)	Examiner Name	Unassigned	
Sheet	1	of	3	Attorney Docket Number	021305-004010US	

			U.S. PATENT DO	CUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-6,489,302	12-03-2002	Wiessler et al.	
	AB	US-5,622,936	04-22-1997	Wiessler et al.	
	AC	US-5,464,826	11-07-1995	Grindey et al.	
	AD	US-4,808,614	02-28-1989	Hertel	
	ΑE	US-2005/0054708	03-10-2005	Michols et al.	
	AF	US-2004/0167079	08-26-2004	Tidmarsh	
	AG	US-2004/0136950	07-15-2004	Ni et al.	
	АН	US-60/910,403		Handisides et al.	
		•			

FOREIGN PATENT DOCUMENTS									
Examiner I	Cite No.1	Foreign Patent Document			Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages	_−6	
IIIIuais		Country Code ³	Number⁴	Kind Code ⁵ (if known)		Applicant of Cited Document	or Relevant Figures Appear	Ľ	
	AI	wo	06/071955	A2	07-06-2006	Threshold Pharmaceuticals Inc.			
	AJ	wo	06/122227	A1	11-16-2006	Threshold Pharmaceuticals Inc.			
	AK	wo	07/035961	A1	03-29-2007	Threshold Pharmaceuticals Inc.			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.S./

Examiner Signature	/Bahar Schmidtmann/	Date Considered	07/07/2011

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Substitute for	form 1449B/PTO	·		Complete if Known		
				Application Number	10/588,409	
INFOR	MATION DIS	CLOS	URE	Filing Date	August 3, 2006	
STATE	EMENT BY A	PPLIC	ANT	First Named Inventor	Tidmarsh, George	
				Art Unit	1624	
(U	se as many sheets as r	necessary)		Examiner Name	Unassigned	
Sheet	2	of	3	Attorney Docket Number	021305-004010US	

	<u> </u>	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		ARANEO et al., "Biweekly Low-Dose Sequential Gemcitabine, 5-Fluorouracil, Leucovorin, and Cisplatin (GFP): A	
	AL	Highly Active Novel Therapy for Metastatic Adenocarcinoma of the Exocrine Pancreas," Cancer Invest., 21(4):489-496 (2003).	
		BRIASOULIS et al., "Phase I Trial of 6-Hour Infusion of Glufosfamide, a New Alkylating Agent With Potentially	
		Enhanced Selectivity for Tumors That Overexpress Transmembrane Glucose Transporters: A Study of the European	
	AM	Organization for Research and Treatment of Cancer Early Clinical Studies Group," <u>J. Clin Oncol</u> , 18(20):3535-3544 (2000).	
	٠	BURRIS et al., "Assessing Clinical Benefit in the Treatment of Pancreas Cancer: Gemcitabine Compared to 5-	
	ÁN	Fluorouracil," <u>Eur. J. Cancer</u> , 33(Suppl 1):S18-S22 (1997).	
••••••		KOZUCH et al., "Irinotecan Combined with Gemcitabine, 5-Fluorouracil, Leucovorin, and Cisplatin (G-FLIP) is an	
	AO	Effective and Noncrossresistant Treatment for Chemotherapy Refractory Metastatic Pancreatic Cancer," The Oncologist, 6:488-495 (2001).	
	AP	NICULESCU-DUVAZ, I., "Glufosfamide (Baxter Oncology)," Curr. Opin. Investig. Drugs, 3(10):1527-1532 (2002).	
	AQ	NOBLE et al., "Gemcitabine. A review of its Pharmacology and Clinical Potential in Non-Small Cell Lung Cancer and Pancreatic Cancer," <u>Drugs</u> , 54(3): 447-472 (1997).	
	AR	ROTHENBERG et al., "A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer," Ann. Oncol., 7:347-353 (1996).	
	AS	STEPHENS, C. D., "Gemcitabine: A New Approach to Treating Pancreatic Cancer," Oncol. Nurs. Forum 25(1):87-93 (1998).	
	ΑТ	ZISKE et al., "Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine," Br. J. Cancer, 89:1413-1417 (2003).	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.S./

Examiner Signature	/Bahar Schmidtmann/	Date Considered	07/07/2011
-----------------------	---------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Substitute	for form 1449B/PTO			Complete if Known		
				Application Number	10/588,409	
INFO	RMATION DIS	CLOS	URE	Filing Date	August 3, 2006	
STA	TEMENT BY A	PPLIC	ANT	First Named Inventor	Tidmarsh, George	
				Art Unit	1624	
	(Use as many sheets as r	necessary)		Examiner Name	Unassigned	
Sheet	3	of	3	Attorney Docket Number	021305-004010US	

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2				
	I AU	"Threshold Pharmaceuticals Announces That a Phase 3 Clinical Trial of Glufosfamide for Treatment of Pancreatic Cancer Did Not Meet Its Primary Endpoint", News Release, Threshold Pharmaceuticals Inc., February 27, 2007.					

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.S./

Examiner Signature	/Bahar Schmidtmann/	Date Considered	07/07/2011

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.